Bide Pharmaceutical announced that shareholders Xinxi Management, Landan Management and Wu Bo plan to reduce their holdings by no more than 3.00% within 3 months of 15 trading days from the date of disclosure of the announcement. Xinxi Management plans to reduce its holdings in bulk transactions by no more than 1.14% and centralized bidding by no more than 0.40%; Landan Management plans to reduce its holdings in bulk transactions by no more than 0.86% and centralized bidding by no more than 0.40%; and Wu Bo plans to reduce its holdings in centralized bidding by no more than 0.20%. The holdings reduction price will be determined according to the market price. The current holdings reduction plan is due to shareholders' capital requirements and will not have a significant impact on the company's governance structure, equity structure, and continued operation.

Bide Pharmaceutical announced that shareholders Xinxi Management, Landan Management and Wu Bo plan to reduce their holdings by no more than 3.00% within 3 months of 15 trading days from the date of disclosure of the announcement. Xinxi Management plans to reduce its holdings in bulk transactions by no more than 1.14% and centralized bidding by no more than 0.40%; Landan Management plans to reduce its holdings in bulk transactions by no more than 0.86% and centralized bidding by no more than 0.40%; and Wu Bo plans to reduce its holdings in centralized bidding by no more than 0.20%. The holdings reduction price will be determined according to the market price. The current holdings reduction plan is due to shareholders' capital requirements and will not have a significant impact on the company's governance structure, equity structure, and continued operation.